Tag: Cancer: Lymphoma
AI Models Can Help Predict In-Hospital Mortality in ICU Patients With Lymphoma
Highest predictive performance was seen for the CatBoost classifier, with AUC of 0.7766
BRCA Mutations Linked to Breast Implant Anaplastic Large Cell Lymphoma
Age-adjusted rate of developing BIA-ALCL 16 times higher for women with mutations versus without
FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma
Significantly improved progression-free survival seen with Monjuvi in combination with rituximab and lenalidomide
Risk for Lymphoma, Skin Cancer Increased in Individuals With Tattoos
Increased risks seen based on twin cohort and case-cotwin studies
Position Statement Developed for Managing Blood Cancers in Pregnancy
Multidisciplinary collaborative approach to care is required for patients with hematological malignancies in pregnancy
ASH: Auto-HCT Not Beneficial for Mantle Cell Lymphoma With Undetectable Residual Disease
Overall survival no better for those receiving autologous HCT plus maintenance rituximab versus rituximab alone
Late-Stage Lymphoma Less Likely for Young With Continuous Medicaid Coverage
Those with newly gained Medicaid, with other Medicaid enrollment patterns more likely to present with stage IV lymphoma
Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
Longer progression-free survival seen with nivolumab + doxorubicin, vinblastine, and dacarbazine (AVD) versus brentuximab vedotin + AVD
Liso-Cel Has Favorable Safety Profile for Outpatients With Large B-Cell Lymphoma
Favorable safety profile seen for relapsed/refractory large B-cell lymphoma patients monitored as outpatients or inpatients
Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard...
Most common SPM subtypes were hematologic malignancies followed by solid tumors, nonmelanoma skin cancers
